1508 studies found for:    Blood Coagulation Disorders: Clinical Trials
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Conditions: Myocardial Ischemia;   Blood Coagulation Disorders;   Coronary Artery Disease;   Heart Valve Diseases
Intervention: Drug: Recombinant Activated Factor VII
2 Active, not recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
3 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
4 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
5 Completed Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: activated recombinant human factor VII;   Drug: vatreptacog alfa (activated)
6 Not yet recruiting Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)
Conditions: Trauma;   Injury;   Bleeding;   Haemorrhage;   Coagulopathy
Interventions: Drug: Fibrinogen concentrate;   Drug: Placebo Comparator
7 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
8 Completed Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
9 Completed Hemodilution and Coagulopathy With 3 Colloids
Condition: Dilutional Coagulopathy
Intervention: Other: Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)
10 Unknown  Study Using Plasma for Patients Requiring Emergency Surgery
Conditions: Hemorrhagic Shock;   Blood Coagulation Disorders;   Blood Products;   Trauma;   Ruptured AAA
Intervention: Drug: Human Plasma
11 Completed Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
12 Active, not recruiting Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
13 Unknown  RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma
Condition: Major Trauma
Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate;   Drug: Fresh Frozen Plasma blood type 0, A, B and AB
14 Completed Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency;   Healthy
Interventions: Drug: catridecacog;   Drug: recombinant factor XIII
15 Completed Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII, long acting
16 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
17 Active, not recruiting Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
18 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
19 Completed Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
20 Completed Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
Conditions: Coronary Heart Disease;   Coagulation Disorder
Intervention: Drug: Anfibatide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years